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ORIGINAL ARTICLE
A comparative analysis of costs of single and dual
rapid HIV and syphilis diagnostics: results from a
randomised controlled trial in Colombia
Carol Dayo Obure,1 Hernando Gaitan-Duarte,2 Ricardo Losada Saenz,2
Lina Gonzalez,2 Edith Angel-Muller,2 Maura Laverty,3 Freddy Perez4
ABSTRACT
Background HIV and congenital syphilis are major
public health burdens contributing to substantial
perinatal morbidity and mortality globally. Although
studies have reported on the costs and cost-effectiveness
of rapid diagnostic tests (RDTs) for syphilis screening
within antenatal care in a number of resource-
constrained settings, empirical evidence on country-
speciﬁc cost and estimates of single RDTs compared with
dual RDTs for HIV and syphilis are limited.
Methods A cluster randomised controlled study design
was used to compare the incremental costs of two
testing algorithms: (1) single RDTs for HIV and syphilis
and (2) dual RDTs for HIV and syphilis, in 12 health
facilities in Bogota and Cali, Colombia. The costs of
single HIV and syphilis RDTs and dual HIV and syphilis
RDTs were collected from each of the health facilities.
The economic costs per woman tested for HIV and
syphilis and costs per woman treated for syphilis deﬁned
as the total costs required to test and treat one woman
for syphilis were estimated.
Results A total of 2214 women were tested in the
study facilities. Cost per pregnant woman tested and
cost per woman treated for syphilis were US$10.26 and
US$607.99, respectively in the single RDT arm. For the
dual RDTs, the cost per pregnant woman tested for HIV
and syphilis and cost per woman treated for syphilis
were US$15.89 and US$1859.26, respectively. Overall
costs per woman tested for HIV and syphilis and cost per
woman treated for syphilis were lower in Cali compared
with Bogota across both intervention arms. Staff costs
accounted for the largest proportion of costs while
treatment costs comprised <1% of the preventive
programme.
Conclusions Findings show lower average costs for
single RDTs compared with dual RDTs with costs
sensitive to personnel costs and the scale of output at
the health facilities.
Trial registration number NCT02454816; results.
INTRODUCTION
HIV and syphilis infection contribute to substantial
perinatal morbidity and mortality worldwide. WHO
and the Joint United Nations Programme on HIV/
AIDS estimates that each year 150 000 (110 000–
190 000) infants are born with HIV1 and 350 000
perinatal deaths are caused by untreated maternal
syphilis at the global level.2 The prevalence of gesta-
tional syphilis in Latin America and the Caribbean
varies by country from 0.08% to 7.0%.3 In 2015, the
incidence of congenital syphilis in Colombia was
3.86 per 1000 live births and the HIV mother to
child transmission rate reported as 3.8%. However,
only 62% of pregnant women were tested for syphilis
during this period in Colombia.4
A number of regional and global initiatives have
been launched for the dual elimination of
mother-to-child transmission of HIVand syphilis.5–7
As part of these efforts, provision of screening and
treatment within antenatal care (ANC) services have
been promoted as an effective and cost-efﬁcient way
to deliver services and reduce the risk of mother to
child transmission of HIVand syphilis while improv-
ing pregnancy outcomes.8 9
In resource-constrained settings, many syphilis
and HIV infections go undiagnosed and women are
lost to follow-up as diagnosis can only be con-
ﬁrmed after laboratory diagnosis which in many
cases takes more than a day.10 As a result, treatment
is delayed and some women never receive treat-
ment. Improvements in syphilis and HIV screening
have been made possible by the introduction of
rapid diagnostic tests (RDTs) that use ﬁnger-prick
whole blood samples and do not require laborator-
ies that are unavailable in many lower level facil-
ities.11 In these settings, RDTs can be used to allow
for early diagnosis and treatment of syphilis using
penicillin during a single visit. Combining the deliv-
ery and implementation of HIV and syphilis ser-
vices, using dual rapid tests for screening could be
useful for allowing reducing testing barriers and
increasing uptake of testing for both HIV and syph-
ilis. Additional advantages of dual HIV/syphilis
RDTs may include streamlined procurement, mini-
mised storage space and simpliﬁed training of
healthcare personnel.12
Dual rapid HIV and syphilis tests reported sensi-
tivity and speciﬁcity estimates comparable to single
HIV and syphilis tests. A recent evaluation of the
SD Bioline HIV/Syphilis Duo test conducted in
Peru found that the sensitivity for the HIV compo-
nent of the dual HIV/syphilis test was 99.1% (95%
CIs 94.8% to 100%) and the speciﬁcity of the HIV
component was 99.4% (95% CI 97.7% to 99.9%).
In Colombia, prior to 2014, syphilis screening
during ANC visits was mainly done using non-
treponemal tests, while HIV diagnosis was done
with two positive enzyme immunoassay (EIA) tests
(or through a rapid test in places where EIA tests
were not available) and conﬁrmed by western blot
analysis.
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Although a number of studies have reported on the costs of
RDTs for syphilis screening in a number of resource-constrained
settings,13–15 empirical evidence on country-speciﬁc cost esti-
mates of single and dual RDTs for syphilis and HIV are limited
particularly in low prevalence settings. Empirical evidence on
the costs of single and dual RDTs is required to improve deliv-
ery of HIV and syphilis screening and health outcomes as well
as for programme planning and budgeting purposes.
The objective of this study was to compare the costs of single
and dual RDTs for HIV and syphilis in Colombia.
METHODS
Study setting
A cluster randomised controlled trial was conducted in 12
health facilities (4 hospitals and 8 health centres) in Bogota and
Cali, Colombia. Clusters were selected through convenience
sampling by choosing health facilities based on a history of at
least 250 ﬁrst antenatal visits per month and similar reported
number of cases for HIV and syphilis. Six clusters were selected
in each city and randomly allocated to the single HIV syphilis
RDT arm (arm A) or dual HIV and syphilis RDT arm (arm B)
with a 1:1 allocation ratio using SAS software (release 9.3). No
other matching of facilities was conducted apart from the
number of ﬁrst antenatal visits per month. Enrolment to the
study was conducted between October 2014 and April 2015
and a total of 2214 pregnant women were enrolled.
Ethical approval
This study is part of an overall assessment of the feasibility,
effectiveness and costs of introducing single and dual RDTs for
syphilis and HIV in ANC services in Colombia.16 Ethical
approval for this study was obtained from the National
University of Colombia and the WHO Ethics Research
Committee. The identiﬁer on the international randomised con-
trolled trials register is NCT02454816.
Cost analysis
A prospective costing study was undertaken from the health
system perspective (patient out of pocket costs were excluded)
using a combination of standard step-down and ingredient-based
costing approaches.17 The ingredients-based costing approach
requires the identiﬁcation and speciﬁcation of each component
of resource used for delivering an individual service to arrive at
a total unit cost. The step-down costing method is used to allo-
cate shared and overhead costs or resources that serve different
services or activities.18
A standardised excel-based cost sheet was used to obtain data
on output and cost information associated with the provision of
syphilis and HIV testing for women accessing ﬁrst ANC visits
using single and dual RDTs for a 6-month period between
October 2014 and March 2015. The main activities of the HIV
and syphilis screening provided as part of ANC were deﬁned
and the resources used to test and treat women described in all
health facilities were included in the study. These consisted of
start-up activities (including development of information, educa-
tion and communication materials (IEC) and training of health
workers), diagnostics and treatment.
Economic costs were estimated which included the value of
all resources used to produce output including those for which
there were no ﬁnancial transactions such as volunteer human
resources and donated goods.
Costs were divided into capital and recurrent costs. Capital
costs comprised the one-off costs of developing IEC materials
and training of health workers. Recurrent costs comprised
personnel, diagnostics and treatment of syphilis and quality
assurance. Personnel costs were calculated based on monthly sal-
aries and allowances and proportion of time spent on syphilis
and HIV testing activities. These costs were determined through
observational time and motion studies implemented in all health
facilities. Time units were multiplied by the relevant clinical
staff salaries to obtain total personnel costs for the period of the
study.
For diagnostic costs, quantities of supplies and the test kits
required to conduct syphilis and HIV tests were obtained from
the health workers and multiplied by the unit price to obtain
unit cost per diagnostic test for syphilis and HIV test in each
intervention arm. The rapid tests used in single RDT arm
(singles tests for HIV/syphilis) were: SD Bioline syphilis 3.0 and
SD Bioline HIV-1/2 3.0. In the dual RDT arm, the dual test SD
Bioline HIV/Syphilis Duo was used. Both tests were provided by
the same manufacturer, Standard Diagnostics, Korea. The cost
of the RDTs were US$1.03 for the single syphilis test; US$1.23
for the single HIV test and US$3.62 for the dual HIV and syph-
ilis test. Total diagnostic costs were then estimated by multiply-
ing the unit cost per test by the number of pregnant women
tested.
Treatment costs for syphilis were estimated based on the
standard recommended treatment for syphilis in pregnant
women using three 2.4 million units (MU) weekly doses of ben-
zathine penicillin for a total of 7.2 MU. Total treatment costs
were obtained by multiplying the number of penicillin doses by
the number of women who received treatment for syphilis at
the health facility. Treatment of HIV was not considered as preg-
nant women testing positive for HIV were referred to the ter-
tiary hospital for conﬁrmation of the diagnosis and treatment.
Costs of treatment for congenital syphilis were not considered
as the pregnant women were not followed-up to birth to deter-
mine the perinatal outcome.
Quality assurance costs reﬂected regular testing of known
positive and negative samples at the reference laboratory to
evaluate the accuracy of the test kits. Cost components included
transport of samples to the central laboratory, monitoring and
supervision, with external quality control assessment conducted.
All cost data were collected in Colombian Pesos and con-
verted to US$2015 using an exchange rate of US$1.00=2,
353.95 Colombian Pesos.
Health outputs
Study outputs included number of pregnant women tested for
HIV and syphilis in each of the facilities, number of women
testing positive for syphilis and HIV and number of women
treated for syphilis. Output data were collected over the same
period as the costs. The economic unit cost per woman tested
and the cost per woman treated were both calculated for each
study facility. The average cost per woman tested was calculated
by dividing the total cost of testing by the number of women
tested. The average cost per woman treated for syphilis deﬁned
as the total costs of resources required to test and treat one
woman for syphilis was calculated by dividing the total costs of
testing and treatment by the number of women treated.
RESULTS
Staff time estimates
The time and motion results revealed average time estimates of
25 min (range 21–29 min) in the single test arm and 29 min
(range 22–44 min) in the dual rapid test arm. Additional infor-
mation on the time estimates for ANC activities and syphilis and
HIV testing across intervention arms during the intervention
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period and a summary of the time estimates for each study facility
are provided in the online supplementary ﬁle 1.
Output measures
A total of 2214 women attending ﬁrst ANC visit were tested for
HIV and syphilis in the study (table 1). Of the 1048 women
tested in the single RDT arm, 3 (0.28%) tested positive for HIV
and 29 (2.8%) tested positive for syphilis. Of those who tested
positive for syphilis, 24/29 women (83%) received timely treat-
ment. In the dual rapid test arm, 1166 women were tested for
HIV and syphilis. Of the women tested, 5 (0.42%) tested posi-
tive for HIV and 20 (1.7%) tested positive for syphilis; 20/20
(100%) of the women who tested positive for syphilis received
timely treatment.
Total costs
Table 2 presents the total facility economic costs and average
unit costs per woman for testing and treatment of syphilis by
treatment arm and health facility level. Average total economic
costs were US$1847.99 for the single RDTarm for a total popu-
lation of 1048 pregnant women across the six facilities. For the
dual RDT arm, average total economic costs were US$3074.43
for a total population of 1166 pregnant women across the six
facilities. In the single RDT arm, total average costs were higher
in the health centres compared with the hospital while in the
dual RDTarm, total average costs were higher in the hospitals.
When total economic costs were analysed by input type
(ﬁgure 1), clinical staff costs accounted for the largest propor-
tion of total costs across both arms (57% in the single RDT arm
and 61% in the dual RDT arm). Diagnostics were the next
largest cost category accounting for 34% of total costs in both
intervention arms. Start-up costs accounted for approximately
7%–4% of total costs in the single RDT and dual RDT arms,
respectively. The quality assurance costs reported reﬂect the
quality assurance implemented during the study, which
accounted for 2% of total costs in the single RDT arm and 1%
of total costs in the dual arm RDT arm. Treatment costs using
2.4 MU weekly doses for a total of 7.2 MU comprised a very
small proportion of total costs accounting for <1% of total
costs in both arms.
Average unit costs
The cost per woman tested using single RDTs at the health facil-
ity level were US$10.26 per pregnant woman tested varying
across health facility type from US$8.10 in the hospital to US
$10.70 in the health centres. Average cost per woman treated
for syphilis was US$607.99 varying between US$413.65 in the
hospital and US$646.86 in the health centres. For the dual RDT
arm, average cost per woman tested was US$15.89 varying
across facility types between US$14.04 in the health centres and
US$17.73 in the hospitals and US$1859.26 per woman treated
for syphilis varying between US$760.07 in the health centres
and US$2958.45 in the hospitals.
Table 3 presents a breakdown of the cost per woman tested
by input type. Unit start-up costs ranged from US$0.62 to US
$0.84. Unit costs for clinical staff salaries accounted for the
largest proportion of unit cost across both intervention arms.
Unit costs for the test kits and other supplies were estimated at
US$3.54 in the single RDT arm and US$5.31 in the dual RDT
arm. Unit costs for quality assurance were US$0.21 and US
$0.19 in Bogota and Cali, respectively.
DISCUSSION
This study uses observation data from clinic-based evaluations
to determine the costs of single and dual RDTs for HIV and
syphilis among pregnant women attending ANC in Bogota and
Cali, Colombia. While a number of studies have reported the
costs of HIV and syphilis testing in high prevalence settings, this
study focuses on a low prevalence setting and is the ﬁrst to
present a comparative cost analysis of the single and dual HIV
and syphilis testing in Colombia.
The study found the average unit cost at the health facility
level for HIV and syphilis testing within ANC to be US$10.26
per woman tested and US$607.99 per woman treated for syphilis
Table 1 Total number of women tested for HIV and syphilis and
treated for syphilis by intervention arm
Single RDT Dual RDT Total
Number of pregnant women
tested
1048 1.166 2214
Number of HIV reactive tests 3 (0.28%) 5 (0.42%) 8 (0.36%)
Number of syphilis reactive
tests
29 (2.8%) 20 (1.7%) 49 (2.21%)
Number of women treated for
syphilis
24 (83%)* 20 (100%) 44 (89.8%)
*Five patients did not receive timely treatment due to lack of adherence to protocol
by the physicians.
RDT, rapid diagnostic test.
Table 2 Total incremental costs for screening and treatment by treatment arm and health facility level
Single RDT arm Dual RDT arm
Hospital (n=1) Health centre (n=5) All Hospital (n=3) Health centre (n=3) All
Start-up costs* US$139.48 US$132.67 US$133.81 US$127.31 US$142.63 US$134.97
Clinical staff salaries US$737.16 US$1117.23 US$1053.89 US$2396.26 US$1323.15 US$1859.71
Diagnostics† US$725.70 US$590.56 US$613.09 US$1090.32 US$973.50 US$1031.91
Treatment‡ US$14.10 US$12.04 US$12.39 US$5.90 US$12.98 US$9.44
Quality assurance US$38.09 US$34.16 US$34.81 US$43.68 US$33.12 US$38.40
Total costs US$1654.59 US$1886.67 US$1847.99 US$3663.48 US$2485.39 US$3074.43
Cost per woman tested US$8.10 US$10.70 US$10.26 US$17.73 US$14.04 US$15.89
Cost per woman treated US$413.65 US$646.86 US$607.99 US$2958.45 US$760.07 US$1859.26
*Includes training costs.
†Diagnostics includes the costs of the test kits and supplies used for testing.
‡Based on three doses of benzathine penicillin.
RDT, rapid diagnostic test.
Bold: Average cost.
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using the single RDT. This was lower than the estimated unit cost
for the dual RDT arm at US$15.89 per pregnant woman tested
and US$1859.26 per woman treated for syphilis. Our unit costs
varied widely across health facilities for both testing arms.
The estimated costs also varied between the two cities. Average
cost per woman tested and average costs per woman treated for
syphilis were higher in Bogota for both arms compared with
Cali. The considerable variation in costs per woman tested across
cities suggests a potential to improve cost efﬁciency across health
facilities through better allocation of existing personnel where
staff costs are high and workload is low. In many of the study
facilities, particularly the study sites in Bogota where the syphilis
and HIV incidences were lower than Cali, the staff workload per
day was low and did not warrant a dedicated staff allocated to
providing HIVand syphilis testing services only.
The lower unit costs in Cali also support the hypothesis that
costs per woman treated for syphilis are highly dependent on
the epidemiology of the disease. Unit costs rise dramatically
where syphilis prevalence is low as there are few women to be
treated for syphilis. However, results from studies suggests that
expanding syphilis screening and treatment into ANC pro-
grammes is cost saving or highly cost-effective in settings with
high maternal syphilis prevalence, low current service coverage
and high healthcare cost as well as in low maternal syphilis
prevalence settings.19–21
This study found higher costs per woman tested using dual
RDTs compared with single RDTs across both cities in
Colombia. While counterintuitive, this result can be explained
by the higher diagnostic test kit cost for the dual test and higher
personnel costs in the sites randomised to the dual RDT arm.
One logical explanation for the high personnel costs in the dual
RDT sites is the relative size of the health facilities given that
three of the study sites were secondary facilities with higher
staff costs. In addition, the higher personnel costs are supported
by underlying data obtained from the time and motion studies
which reveal higher time estimates for testing using the dual
RDTs (average 29 min) compared with the single RDTs (average
25 min).
The unit costs derived from this study are higher than those
reported in a recent study conducted in Peru, another low syph-
ilis and HIV prevalence setting.20 The Peruvian study found
cost estimates ranging from US$2.70 to US$3.19 and US$295
to US$369 per woman tested with rapid single test (RST) com-
pared with US$3.60 to US$5.55 and US$740 to US$1454 per
woman tested with rapid plasma reagin (RPR). The lower costs
reported for the Peruvian study is largely a reﬂection of the
presence of economies of scale in implementation where ﬁxed
costs such as personnel are spread over a large volume of
output. Overall, the high average costs per woman tested and
treated in this present study can be attributed to the low
numbers of women testing positive for syphilis in this setting.
Like any other costing study, this study has a number of lim-
itations that should be mentioned. First, we acknowledge the
possible drawback of matching using a convenience sample,
Figure 1 Breakdown of total costs by input type across intervention arms. RDT, rapid diagnostic test.
Table 3 Breakdown of cost per woman tested in US$2015
Single RDT arm Dual RDT arm
Hospital
(n=1)
Health
centre (n=5)
Hospital
(n=3)
Health
centre (n=3)
Start-up costs* $0.68 $0.75 $0.62 $0.84
Clinical staff
salaries
$3.69 $6.02 $11.58 $7.77
Diagnostics† $3.54 $3.54 $5.31 $5.31
Quality
assurance
$0.19 $0.19 $0.21 $0.14
Cost per woman
tested
$8.10 $10.70 $17.72 $14.06
*Includes training costs.
†Diagnostics includes the costs of the test kits and other supplies used for testing.
RDT, rapid diagnostic test.
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which may have caused biased research results and thus limiting
the wider applicability of the study results. Second, although
HIV testing was provided in the context of this study, the study
did not attempt to estimate the costs of HIV treatment as
patients who tested positive were referred to a central location
for antiretroviral treatment (ART) treatment. Third, no effect-
iveness measures were obtained from the trial limiting the
ability to conduct a cost-effectiveness analysis. As there was no
retesting of samples with a reference standard, the true preva-
lence of syphilis in the study facilities is unknown. Further
research is therefore required to determine the cost-effectiveness
of the two testing algorithms in Colombia.
CONCLUSION
As rapid test for HIV and syphilis are rolled out, this study pro-
vides valuable information for policymakers and public health
practitioners seeking to implement rapid diagnostics for syphilis
and HIV screening programmes in ANC settings in Colombia
and other low prevalence settings. The results of the study show
lower average costs for single RDTs compared with dual RDTs.
However, it is worth noting that if the price of the dual RDTs
were lowered due to increased demand, the unit costs per
woman tested would likely reduce. In conclusion, although this
study ﬁnds higher unit costs for dual RDTs compared with
single RDTs, other considerations beyond costs should be taken
into account when making decisions on the roll out of rapid
diagnostics for HIV and syphilis.
Key messages
▸ Average unit costs for single rapid diagnostic tests (RDTs)
were lower compared with dual RDTs in the study sample.
▸ Human resource costs are the major cost driver across the
two testing strategies.
▸ Other considerations beyond costs such as increased testing
uptake for both HIV and syphilis should be taken into
account by decision makers.
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